Background: Urinary albumin excretion between 20 to 200 mg per litre is defined as microalbuminuria (MAU). MAU acts as a marker for endothelial cell destruction and is associated with atherosclerosis in both diabetics and non-diabetics. This study aimed to assess the MAU prevalence in nondiabetic patients with myocardial infarction.Methods: A cross-sectional study was conducted at tertiary care hospital. Among non-diabetic patients with myocardial infarction. The study was conducted from October 2019 to March 2020. All patients were subjected to complete physical examination, electrocardiography (ECG) and echocardiography. Quantitative determination of MAU was done in a urine sample. Diagnostic coronary angiogram was performed for all patients. Appropriated statistical tests were applied.Results: Among 80 study participants, 73.75% were men, and 26.25% were women. Smoking habit was present among 60%, and 56.25% were hypertensive. The prevalence of microalbuminuria was 27.5%. A statistically significant difference was seen between TIMI scoring and presence of MAU (p<0.001). The difference in vessels type between the microalbuminuria status was found to be significant (p=0.005).Conclusions: Evidence from this study shows that the presence of MAU had a strong association between myocardial infarction and its application as a risk factor of cardiovascular diseases in general non-diabetic population proves practical.
Background: Hepatitis B virus (HBV) infection affects more than 2 billion individuals globally HBV. The chance of dying from liver cirrhosis, acute fulminant liver disease, or hepatocellular carcinoma (HCC) is present in 240 million of these chronic HBV carriers(HCC). Aims and Objectives: This study aims to assess the anti-HBs antibody titer level against various levels of healthcare workers (HCWs) and to assess the need for booster dose hepatitis B vaccination. Materials and Methods: This study was conducted at Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Melmaruvathur, Tamil Nadu, India, from July 2022 to December 2022. A total of 218 HCWs were divided into two groups: Group A (vaccinated ≥5 years ago) and Group B (vaccinated in past 5 years). The serum from 2 mL blood was separated and tested for anti HBs antibody titer by electrochemiluminescense immunoassay method. Results: The mean and standard deviation values of Anti-HBsAg titer between Group A and Group B was not statistically significant (P=0.08467). Conclusion: Our study demonstrates that people who have had vaccinations are unsure of whether they are responders or non-responders, and to determine this, they must have had their titer evaluated only 1–2 months after receiving their third dosage of hepatitis B vaccine. As a result, they still run the risk of contracting hepatitis B and strongly need a booster dose of the hepatitis B vaccine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.